DOI: https://doi.org/10.22141/2224-0586.7.86.2017.116885

Morpholinium-3-methyl-1,2,4-triazolyl-5-thioacetate in comprehensive correction of cognitive impairment in patients with acute myocardial infarction

K.S. Stroienko, A.A. Khyzhniak, V.V. Nikonov

Abstract


The paper deals with the study of morpholinium-3-methyl-1,2,4-triazolyl-5-thioacetate impact in correction of cognitive disorders in patients with acute myocardial infarction. The study enrolled 70 patients with acute myocardial infarction and cognitive impairment aged up to 60 years without burdened neurological history. Cognitive disorders were revealed by means of cognitive dysfunction tests (Mini-Mental State Examination, clock drawing test, 10 words memorizing). Additionally, C-reactive protein and blood cortisol content was assessed (day 1 and day 10 of the disease). Depending on the type of treatment, the patients were divided into 2 groups: group 1 (n = 35) — standard treatment scheme in acute myocardial infarction, group 2 (n = 35) — standard treatment in combination with morpholinium 3-methyl-1,2,4-triazolyl-5 thioace­tate. During the study, the patients showed increased cortisol and C-reactive protein levels within the first 24 hours of the di­sease — 12.10 ± 0.04 and 8.20 ± 0.01, respectively. During the treatment, group 1 was revealed to have a decrease in cortisol levels to 10.90 ± 0.04, while patients of group 2 had significant reduction of cortisol content to 8.20 ± 0.04 (Р < 0.05). C-reactive protein values in group 2 were reduced to 5.10 ± 0.01, while in group 1 they were within the range of 8.10 ± 0.01 (Р < 0.05). The test outcomes have shown that cognitive dysfunction mani­fests in the form of attributable cognitive impairment in 59 %, mild dementia — in 21 %, moderate dementia — in 20 % of patients with acute myocardial infarction within the first 24 hours of the disease. Morpholinium 3-methyl-1,2,4-triazolyl-5 thioacetate added to standard treatment scheme resulted in significantly decreased cognitive dysfunction in 73 % of patients, while in patients who underwent standard treatment, regression of cognitive impairment was revealed only in 46 % of cases. The study has made it possible to establish that application of morpholinium 3-methyl-1,2,4-triazolyl-5 thioacetate contributes to a significant improvement of cognitive dysfunction, while in patients who underwent standard treatment, regression of cognitive impairment was substantially decreased. The paper deals with issues concerning improvement of diagnosis and optimization of management of cerebral insufficiency in patients with acute myocardial infarction.

Keywords


acute myocardial infarction; cerebrovascular pathology; cognitive impairment; morpholinium-3-methyl-1,2,4-triazolyl-5-thioacetate

References


http://www.who.int/en/ [Електронний ресурс].

Benjamin E.J., Blaha M.J., Chiuve S.E., Cushman M., Das S.R., Deo R. Heart Disease and Stroke Statistics — 2017 Update: A Report From the American Heart Association // Circulation. — 2017. — 135(10). — e146-e603.

Кожухов С.Н. Научные доказательства оптимизации терапии больных c хронической сердечной недостаточностью на фоне ишемической болезни сердца // Серцева недостатність та коморбідні стани. — 2017. — № 1.

Гадзюк В.А. Аналіз захворюваності на ішемічну хворобу серця в Україні // Український кардіологічний журнал. — 2014. — № 3. — C. 45-52.

Melanie Nichols. Evropean cardiovascular disease statistics 2012 edition // Melanie Nichols, Nick Townsend, Peter Scarborough, Mike Rayner. — 2012. — Р. 1-125.

Стадник С.М. Неврологічний катамнез хворих з різними формами гострої кардіальної патології // Медицина неотложных состояний. — 2012. — № 4(43). — C. 87-93.

Слимова Н.Р. Инновационные подходы к нейропротекции в кардиологии // Здоров’я України. — 2013. — № 2.

Стадник С.М., Рудницький М.К., Куценко І.З. Гострі психози в реанімаційному періоді лікування гострого інфаркту міокарду // Здоров’я України. — 2013. — № 3(26). — C. 34-35.

Бильченко А.В. Кардиогенная деменция // Здоров’я України. Кардиология. — 2014. — № 1. — C. 7-8.

Гераскина Л.А., Фонякин А.В. Общие подходы и нейрометаболическая терапия в профилактике и лечении кардиогенной энцефалопатии // Медицинский вестник. — 2012. — № 7. — http://www.medvestnik.ru.

Царенко С.В. Нейрореаниматология. Интенсивная терапия черепно-мозговой травмы. — М.: Медицина, 2006. — 352 с.

Dowdy D.W., Eid M.P., Sedrakyan A., Mendez-Tellez P.A., Pronovost P.J., Herridge M.S., Needham D.M. Quality of life in adult survivors of critical illness: A systematic review of the literature // Intensive Care Medicine. — 2015. — 31(5). — Р. 611-620.

Хижняк А.А. Вплив загальної анестезії на ступінь когнітивних змін у хворих похилого віку з ургентною хірургічною патологією // Медицина неотложных состояний. — 2015. — № 1. — С. 132-135.




Copyright (c) 2017 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта